Company intelligence / Profile preview
TechnoGenesys
St. Louis, Missouri, USAtechnogenesys.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
TechnoGenesys is developing a first-in-class dual-action small molecule inhibitor, Mahatinib ((R)-9b), which targets both ACK1 kinase and the androgen receptor. The compound has shown promise in overcoming resistance to current therapies for prostate cancer and demonstrates immune-regulatory activity. A first-in-human Phase I clinical trial ("PHAROS") will begin in early/mid 2025 with initial proof-of-concept data expected by Q3 2025. The company also plans to develop companion diagnostics for personalized medicine approaches
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeKinase inhibitorAndrogen receptor antagonist
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major pharma or biotech partnerships disclosed as of June 2025; NIH/NCI grant funding received for clinical trialsOpen to VC/pharma investment partners for future rounds
Beyond the preview
Go deeper on TechnoGenesys.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TechnoGenesys.